Liver health has not been at the forefront of complications tracked for disease prevention, as traditionally done for diabetic retinopathy, nephropathy, or neuropathy. Liver steatosis affects approximately two out of three people with type 2 diabetes and places them at an increased risk for metabolic dysfunction–associated steatohepatitis (MASH), cirrhosis, hepatocellular carcinoma (HCC), and overall liver-related mortality.
Most individuals and their health care professionals remain unaware of the severe hepatic or extrahepatic health risks associated with MASLD and the need for early identification. In recognition of this knowledge gap and the rising prevalence of MASLD, this consensus report is a call to action to screen for liver fibrosis and risk stratify people with prediabetes or type 2 diabetes, in particular if obesity is also present (Kenneth Cusi, et al Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025; dci240094. https://doi.org/10.2337/dci24-0094).
At CIMA Sciences, we are ready to meet this call for action through the timely application of OWLiver test. In fact, a study published in 2021 showed that the combination of FIB-4 and OWLiver® provides an accurate, quick serum-based, easy to use test as a screening tool in a high risk T2D population (Mayo R. et al. Hepatology,Oct. 2021. Hepatology, Vol 74, Number 1).
The OWLiver test available nation-wide with an approved CPT PLA code by the American Medical Association in January 2024.
